Please ensure Javascript is enabled for purposes of website accessibility

Why Vaxart Stock Jumped Today

By Joe Tenebruso – Aug 11, 2020 at 7:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus vaccine maker is progressing with the clinical trial process.

What happened

Shares of Vaxart (VXRT 2.79%) rose sharply on Tuesday, furthering the gains accrued since the biotech company filed an Investigational New Drug (IND) application for its oral coronavirus vaccine on Aug. 10. By the close of trading, Vaxart's stock was up 14.4% after surging as much as 32.7% earlier in the day.

So what 

Vaxart filed its IND application with the U.S. Food and Drug Administration (FDA) on Monday morning. It's essentially a request to begin testing its experimental vaccine on people in a clinical trial. "Filing the IND is the first major step of many we are taking to advance our oral vaccine in the prevention of COVID-19," Vaxart Chief Scientific Officer Sean Tucker said in a press release. 

A person points to an upwardly sloping line that's above a flat line.

Vaxart's stock rallied on Tuesday. Image source: Getty Images.

Vaxart's vaccine candidate is unique in that it's a tablet rather than an injection. CEO Andrei Floroiu says this form offers several benefits, including being easier to store, transport, and administer to patients.

Now what

Vaxart's gains are interesting because they came on a day when many other vaccine stocks fell. Russia's announcement that it had approved the world's first coronavirus vaccine sent many COVID-19 stocks into a tailspin -- but not Vaxart.

Perhaps that's telling. It might signify the market's recognition of the potential logistical advantages of Vaxart's oral vaccine, which could set it apart from other candidates if it proves both safe and effective.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$2.21 (2.79%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.